L3VLUP
ProSign in

IONS · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

IONSJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • IONS
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterIONSJNJ
Q3 202015 holders, $2.1bn30 holders, $26.2bn
Q4 202014 holders, $2.5bn32 holders, $26.6bn
Q1 20219 holders, $1.9bn31 holders, $25.3bn
Q2 202110 holders, $1.8bn37 holders, $25.6bn
Q3 20218 holders, $1.4bn40 holders, $24.1bn
Q4 20219 holders, $1.3bn33 holders, $25.2bn
Q1 20229 holders, $1.6bn35 holders, $28.2bn
Q2 202212 holders, $1.6bn33 holders, $26.9bn
Q3 202211 holders, $1.5bn36 holders, $25.4bn
Q4 20229 holders, $1.2bn35 holders, $27.6bn
Q1 20237 holders, $1.0bn42 holders, $24.5bn
Q2 202310 holders, $1.3bn38 holders, $25.0bn
Q3 202312 holders, $1.4bn37 holders, $18.9bn
Q4 202314 holders, $1.9bn31 holders, $19.0bn
Q1 202415 holders, $1.7bn32 holders, $19.7bn
Q2 202417 holders, $2.1bn35 holders, $20.4bn
Q3 202416 holders, $2.1bn28 holders, $22.3bn
Q4 202411 holders, $1.7bn37 holders, $20.4bn
Q1 202510 holders, $1.5bn32 holders, $20.5bn
Q2 202513 holders, $2.1bn31 holders, $18.4bn
Q3 202518 holders, $3.6bn32 holders, $23.7bn
Q4 202515 holders, $4.9bn29 holders, $27.8bn
Q1 202616 holders, $5.0bn34 holders, $35.6bn
Q2 202613 holders, $5.5bn33 holders, $39.1bn
IONS

Ionis Pharmaceuticals Inc

Holders
13
Reported value
$2.1bn
Buyers
8
Sellers
5

Breadth +3 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
JNJ

Johnson & Johnson

Holders
31
Reported value
$18.4bn
Buyers
15
Sellers
16

Breadth -1 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2025

Among the 38 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only IONS (7)

ARK Investment Management LLC, Artisan Partners LP, Capital World Investors, Hudson Bay Capital Management LP, PDT Partners LLC, Schonfeld Strategic Advisors LLC, Voloridge Investment Management LLC

Only JNJ (25)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Caxton Associates LLP, D. E. Shaw & Co., Dodge & Cox, Eisler Capital Management Ltd, GAMCO Investors Inc, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Markel Group Inc, Marshall Wace LLP, MFS Investment Management, Neuberger Berman Group LLC, Point72 Asset Management LP, Quantbot Technologies LP, Renaissance Technologies LLC, T. Rowe Price Associates Inc, Verition Fund Management LLC, Winton Group Ltd

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →